Mylan (MYL) Unit Launches Generic Clarinex Tabs
Tweet
Share
E-mailGet Alerts MYL Hot Sheet
Join SI Premium – FREE
Mylan Inc. (Nasdaq: MYL) announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Desloratadine Tablets, 5 mg, the generic version of Schering-Plough's Clarinex allergy medication. Mylan previously received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Desloratadine Tablets, 5 mg, and is shipping this product immediately.
Desloratadine Tablets, 5 mg, had U.S. sales of approximately $194.6 million for the 12 months ending March 31, 2012, according to IMS Health.
Desloratadine Tablets, 5 mg, had U.S. sales of approximately $194.6 million for the 12 months ending March 31, 2012, according to IMS Health.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sui Group's chief investment officer resigns, effective July 2026
- MicroVision launches semiconductor unit from acquired Luminar division
- Performance Shipping extends tanker charter at $40,500/day average rate
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
